[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Entrada Therapeutics (TRDA) reported an insider share sale by a major holder. On 11/14/2025, an entity affiliated with director and 10% owner Kush M. Parmar, M.D., Ph.D., sold 200,000 shares of Entrada Therapeutics common stock in an open-market transaction at a weighted average price of $8.80 per share, with individual sale prices ranging from $8.80 to $9.023.

Following this transaction, 5AM Ventures V, L.P. is shown as beneficially owning 2,963,066 shares indirectly, and 5AM Opportunities I, L.P. is shown as beneficially owning 1,093,313 shares indirectly. Dr. Parmar may be deemed to share voting and investment power over these positions through general partner entities, but he disclaims beneficial ownership except to the extent of his pecuniary interest.

Insights

Equity Ownership Analyst

Director and 10% owner reports sale of 200,000 shares; retains a substantial indirect stake through venture funds.

This Form 4 reports that **Kush M. Parmar**, a **director and 10% owner** of **Entrada Therapeutics, Inc. (TRDA)**, sold **200,000 shares of common stock** on 11/14/2025. The weighted average sale price was $8.8 per share, with individual trades occurring between $8.80 and $9.023. After this transaction, he reports indirect beneficial ownership of **2,963,066 shares** through **5AM Ventures V, L.P.** and **1,093,313 shares** through **5AM Opportunities I, L.P.**

The filing clarifies that these holdings are indirect. Control flows through general partner entities (**5AM Partners V, LLC** and **5AM Opportunities I (GP), LLC**), where Dr. Parmar is a managing member and may share voting and investment power. He formally disclaims beneficial ownership beyond his economic interest, which is standard language for fund managers and signals a fund-structure-driven, not personal, registration of the shares.

The immediate effect is a reduction in the reported indirect position by 200,000 shares at prices near $9, while leaving a sizable remaining stake via the two funds. A key detail to watch is whether similar Form 4s show an ongoing pattern of sales by these entities or whether this appears as an isolated transaction around November 2025. Repeated transactions over subsequent months would give a clearer picture of how the reporting person and affiliated funds are adjusting their exposure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARMAR KUSH

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		S		200,000	D	$8.8(1)	2,963,066	I	By 5AM Ventures V, L.P.(2)
Common Stock								1,093,313	I	By 5AM Opportunities I, L.P.(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.023 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein.

3. Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.

	/s/ Kush Parmar	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Entrada Therapeutics (TRDA) report on this Form 4?

The filing reports that on 11/14/2025, an entity affiliated with director and 10% owner Kush M. Parmar, M.D., Ph.D. sold 200,000 shares of Entrada Therapeutics common stock in an open-market transaction.

At what price were the Entrada Therapeutics (TRDA) shares sold in the reported transaction?

The 200,000 shares of Entrada Therapeutics common stock were sold at a weighted average price of $8.80 per share, with individual trades executed at prices ranging from $8.80 to $9.023 inclusive.

How many Entrada Therapeutics (TRDA) shares does 5AM Ventures V, L.P. hold after the sale?

After the reported sale, 5AM Ventures V, L.P. is shown as beneficially owning 2,963,066 shares of Entrada Therapeutics common stock, held indirectly.

How many Entrada Therapeutics (TRDA) shares does 5AM Opportunities I, L.P. hold according to the filing?

The filing shows that 5AM Opportunities I, L.P. beneficially owns 1,093,313 shares of Entrada Therapeutics common stock, also held indirectly.

What is Kush M. Parmar’s relationship to Entrada Therapeutics (TRDA)?

Kush M. Parmar, M.D., Ph.D. is identified as both a director and a 10% owner of Entrada Therapeutics, Inc. through affiliated investment entities.

Does Kush M. Parmar claim full beneficial ownership of the Entrada Therapeutics (TRDA) shares held by the funds?

The filing states that Dr. Parmar may be deemed to share voting and investment power over shares held by 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., but he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.

How were the multiple trade prices for the Entrada Therapeutics (TRDA) insider sale handled in the filing?

The filing explains that the reported price of $8.80 per share is a weighted average price for multiple transactions executed at prices ranging from $8.80 to $9.023, and notes that detailed trade data is available upon request.